AU2017248276B2 - Methods of treating ocular conditions - Google Patents

Methods of treating ocular conditions Download PDF

Info

Publication number
AU2017248276B2
AU2017248276B2 AU2017248276A AU2017248276A AU2017248276B2 AU 2017248276 B2 AU2017248276 B2 AU 2017248276B2 AU 2017248276 A AU2017248276 A AU 2017248276A AU 2017248276 A AU2017248276 A AU 2017248276A AU 2017248276 B2 AU2017248276 B2 AU 2017248276B2
Authority
AU
Australia
Prior art keywords
compound
formula
iib
nasal cavity
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017248276A
Other languages
English (en)
Other versions
AU2017248276A1 (en
Inventor
Douglas Michael Ackermann Jr.
James Loudin
Kenneth J. Mandell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oyster Point Pharma Inc
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of AU2017248276A1 publication Critical patent/AU2017248276A1/en
Application granted granted Critical
Publication of AU2017248276B2 publication Critical patent/AU2017248276B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017248276A 2016-04-07 2017-04-06 Methods of treating ocular conditions Active AU2017248276B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
US62/319,648 2016-04-07
PCT/US2017/026385 WO2017177024A1 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
AU2017248276A1 AU2017248276A1 (en) 2018-11-22
AU2017248276B2 true AU2017248276B2 (en) 2023-07-13

Family

ID=58549326

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017248276A Active AU2017248276B2 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Country Status (19)

Country Link
US (3) US10709707B2 (OSRAM)
EP (2) EP3970724A1 (OSRAM)
JP (3) JP7090551B2 (OSRAM)
KR (2) KR102512777B1 (OSRAM)
CN (3) CN114432313A (OSRAM)
AU (1) AU2017248276B2 (OSRAM)
DK (1) DK3439661T3 (OSRAM)
EA (1) EA201892265A1 (OSRAM)
ES (1) ES2893126T3 (OSRAM)
IL (3) IL299204A (OSRAM)
MX (2) MX385698B (OSRAM)
MY (1) MY199237A (OSRAM)
NZ (1) NZ746468A (OSRAM)
PH (1) PH12018502154A1 (OSRAM)
PT (1) PT3439661T (OSRAM)
SG (1) SG11201808650QA (OSRAM)
TW (2) TWI876258B (OSRAM)
WO (1) WO2017177024A1 (OSRAM)
ZA (1) ZA201807438B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
EP3848028B9 (en) 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
ES3039903T3 (en) * 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
IL308372A (en) * 2021-05-07 2024-01-01 Oyster Point Pharma Inc Co-therapy using a vector and a nicotinic agonist
WO2026080563A1 (en) 2024-10-09 2026-04-16 Oyster Point Pharma, Inc. Simpinicline oral formations and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
WO2010065443A1 (en) * 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010147938A2 (en) * 2009-06-17 2010-12-23 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
CA2468705A1 (en) 2001-11-29 2003-06-05 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2006040680A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
WO2006100075A2 (en) 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
WO2008093227A1 (en) 2007-02-02 2008-08-07 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
US20110263629A1 (en) 2008-09-05 2011-10-27 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
KR20110091501A (ko) * 2008-10-14 2011-08-11 싸이코제닉스 아이엔씨. 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도
US9145396B2 (en) * 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
KR102043077B1 (ko) 2011-10-20 2019-11-11 노파르티스 아게 알파 ７ 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성을 예측하는 바이오마커
EP2786142A4 (en) 2011-11-30 2015-07-22 Diagnostear Ltd DIAGNOSIS OF THE DRY EYE
EP3848028B9 (en) * 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
DK3439661T3 (da) * 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
WO2010065443A1 (en) * 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010147938A2 (en) * 2009-06-17 2010-12-23 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands

Also Published As

Publication number Publication date
ES2893126T3 (es) 2022-02-08
KR102512777B1 (ko) 2023-03-23
IL299204A (en) 2023-02-01
IL262102B (en) 2022-03-01
BR112018070497A2 (pt) 2019-01-29
CN109310692B (zh) 2022-01-25
TW201737917A (zh) 2017-11-01
SG11201808650QA (en) 2018-10-30
WO2017177024A8 (en) 2018-11-08
AU2017248276A1 (en) 2018-11-22
JP2019513759A (ja) 2019-05-30
MX385698B (es) 2025-03-18
IL262102A (en) 2018-11-29
TW202320785A (zh) 2023-06-01
CN114432313A (zh) 2022-05-06
KR20230010813A (ko) 2023-01-19
EP3439661B1 (en) 2021-08-04
JP2022120125A (ja) 2022-08-17
ZA201807438B (en) 2024-09-25
US20200345734A1 (en) 2020-11-05
DK3439661T3 (da) 2021-10-18
JP2024103594A (ja) 2024-08-01
PT3439661T (pt) 2021-09-30
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
EP3439661A1 (en) 2019-02-13
MX2018012230A (es) 2019-03-28
ES2893126T8 (es) 2022-05-23
US20250000861A1 (en) 2025-01-02
US20190201397A1 (en) 2019-07-04
WO2017177024A1 (en) 2017-10-12
KR20190005859A (ko) 2019-01-16
CN109310692A (zh) 2019-02-05
MY199237A (en) 2023-10-22
IL290069B2 (en) 2023-05-01
KR102485299B1 (ko) 2023-01-06
IL290069A (en) 2022-03-01
TWI876258B (zh) 2025-03-11
CN114533737B (zh) 2024-05-31
JP7090551B2 (ja) 2022-06-24
MX2021010399A (es) 2022-01-18
NZ746468A (en) 2023-06-30
IL290069B1 (en) 2023-01-01
TWI790997B (zh) 2023-02-01
CN114533737A (zh) 2022-05-27
EA201892265A1 (ru) 2019-04-30
NZ785093A (en) 2024-07-05
EP3970724A1 (en) 2022-03-23
CA3020170A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
US20250000861A1 (en) Methods of treating ocular conditions
US12576080B2 (en) Use of varenicline for treating ocular conditions
HK40063370A (en) Methods of treating ocular conditions
CA3020170C (en) Methods of treating ocular conditions
HK40004067B (en) Methods of treating ocular conditions
EA047371B1 (ru) Применение соединения при лечении сухости глаз или дискомфорта в глазах
EA040442B1 (ru) Применение соединения при лечении сухости глаз или дискомфорта в глазах
BR112018070497B1 (pt) Métodos e formulações farmacêuticas para tratamento de condições oculares
HK1242208A1 (en) Methods of treating ocular conditions
HK1242208B (en) Methods of treating ocular conditions

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF A CO-INVENTOR TO READ ACKERMANN JR., DOUGLAS MICHAEL

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 13 NOV 2023

FGA Letters patent sealed or granted (standard patent)